NeuroBo Pharmaceuticals (NASDAQ:NRBO) versus InterCure (NASDAQ:INCR) Head to Head Review

NeuroBo Pharmaceuticals (NASDAQ:NRBO) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Institutional & Insider Ownership

1.4% of NeuroBo Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 1.1% of NeuroBo Pharmaceuticals shares are owned by insiders. Comparatively, 0.2% of InterCure shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent recommendations for NeuroBo Pharmaceuticals and InterCure, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroBo Pharmaceuticals	0	0	1	0	3.00
InterCure	0	0	0	0	0.00

NeuroBo Pharmaceuticals currently has a consensus price target of $10.00, suggesting a potential upside of 344.72%. Given NeuroBo Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts clearly believe NeuroBo Pharmaceuticals is more favorable than InterCure.

Profitability

This table compares NeuroBo Pharmaceuticals and InterCure’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeuroBo Pharmaceuticals	N/A	-189.12%	-122.31%
InterCure	N/A	N/A	N/A

Volatility and Risk

NeuroBo Pharmaceuticals has a beta of -0.26, indicating that its share price is 126% less volatile than the S&P 500. Comparatively, InterCure has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500.

Earnings & Valuation

This table compares NeuroBo Pharmaceuticals and InterCure”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroBo Pharmaceuticals	N/A	N/A	-$12.47 million	N/A	N/A
InterCure	$272.67 million	0.24	-$16.83 million	N/A	N/A

NeuroBo Pharmaceuticals has higher earnings, but lower revenue than InterCure.

About NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company’s therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

About InterCure

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.